Abstract
Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.
| Original language | Italian |
|---|---|
| Pages (from-to) | 147-153 |
| Number of pages | 7 |
| Journal | Minerva Chirurgica |
| Volume | 70 |
| Issue number | 2 |
| Publication status | Published - Apr 1 2015 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Trattamento del "persistent postmastectomy pain" con Lidocaina cerotto 5%. / Cruto, M. E.; Baricocchi, E.; Battistella, M.; Bona, F.; Giacoletto, G.; Iacobellis, A.; Moselli, N.; Palomba, G.; Sardo, E.; Savojardo, M.; Suita, L.; Zocca, E.; Debernardi, F.
In: Minerva Chirurgica, Vol. 70, No. 2, 01.04.2015, p. 147-153.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Trattamento del "persistent postmastectomy pain" con Lidocaina cerotto 5%
AU - Cruto, M. E.
AU - Baricocchi, E.
AU - Battistella, M.
AU - Bona, F.
AU - Giacoletto, G.
AU - Iacobellis, A.
AU - Moselli, N.
AU - Palomba, G.
AU - Sardo, E.
AU - Savojardo, M.
AU - Suita, L.
AU - Zocca, E.
AU - Debernardi, F.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.
AB - Persistent postmastectomy pain (PPMP) syndrome is characterized by neuropathic pain that develops following surgery in breast cancer patients. The reported incidence of PPMP ranges between 30% and 50% and is estimated to increase as the number of women surviving cancer continues to rise. Though effective, today's drug treatments are poorly tolerated, limiting their use and reducing adherence to therapy. Since neuropathic pain is localized, international guidelines suggest that topical treatment with 5% Lidocaine medicated plaster either alone or combined with systemic drugs can be considered for pain management. In this retrospective study we reviewed the medical records of 11 patients treated with 5% lidocaine medicated plaster for moderate-to-severe PPMP at our institute between November 2013 and October 2014. Analysis showed that treatment with 5% Lidocaine medicated plaster, either alone or in combination with systemic drugs, achieved significant pain control already after the first week of therapy. The effectiveness and tolerability of 5% Lidocaine medicated plaster we observed suggests that it is a viable option in the management of PPMP.
UR - http://www.scopus.com/inward/record.url?scp=84948067978&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84948067978&partnerID=8YFLogxK
M3 - Articolo
C2 - 25815700
AN - SCOPUS:84948067978
VL - 70
SP - 147
EP - 153
JO - Minerva Chirurgica
JF - Minerva Chirurgica
SN - 0026-4733
IS - 2
ER -